Looks like we’ll all have to wait a bit longer for AI to help with the dishwasher. What’s one AI breakthrough you’re waiting for? Thank you Stuart (Stu) Bailey, Ashwini Ghogare, PhD, Philipp Harbach, Anja Jatsch and Immanuel Schweizer for passing the question. #AI360View
Info
We are Merck KGaA, Darmstadt, Germany and its global affiliates. We are a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Privacy Statement: https://xmrrwallet.com/cmx.pwww.emdgroup.com/en/privacy-statement.html
- Website
-
http://xmrrwallet.com/cmx.pwww.emdgroup.com
Externer Link zu Merck KGaA, Darmstadt, Germany
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Darmstadt
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Phamaceutical, Chemical, Technology und Science
Orte
-
Primär
Wegbeschreibung
Frankfurter Str. 250
Darmstadt, 64293, DE
-
Wegbeschreibung
290 Concord Rd.
Billerica, Massachusetts 64293, US
-
Wegbeschreibung
One Technology Place
Rockland, Massachusetts 02370, US
Beschäftigte von Merck KGaA, Darmstadt, Germany
Updates
-
Merck KGaA, Darmstadt, Germany hat dies direkt geteilt
🌐 NEWS: Positive Results for TGCT Patients in Global Phase III Study 🌐 An investigative treatment being developed by our partner 和誉医药 Abbisko Therapeutics shows potential to meet unmet needs for patients with Tenosynovial Giant Cell Tumor (TGCT). 👉 Read more here: https://xmrrwallet.com/cmx.plnkd.in/eN4Tt3wm #AsOneForPatients #PhaseIII #TGCT #Oncology
-
Merck KGaA, Darmstadt, Germany hat dies direkt geteilt
Exciting news! We’re investing $76 million to triple our Antibody-Drug Conjugate (ADC) manufacturing capacity in St. Louis, Missouri. This expansion reinforces our commitment to advancing these cutting-edge novel therapies, and to our clients and ultimately patients. ADCs precisely target cancer cells, sparing healthy ones—one of the most promising advances in cancer treatment today. Together with our clients, we’re unlocking ADCs’ full potential to impact life and health with science. Learn more here: http://xmrrwallet.com/cmx.pms.spr.ly/6048W3d52
-